Kymera in the News
Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.
Featured Perspectives
December 16, 2025
From Target Selection to POC in Patients: Completing the Initial Human Translation of STAT6 Degradation
Nello Mainolfi, PhD, Founder, President and CEO
February 12, 2025
A Revolution in Immunology: Creating New Possibilities with Oral Medicines
Arsalan Shabbir, MD, PhD, Vice President, Clinical Development
April 24, 2025
A New Era of Possibility: Addressing Coveted Undrugged Targets
Juliet Williams, PhD, Head of Research
Showing 48 news results
December 8, 2025
STAT News: Kymera drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial
December 8, 2025
Endpoints News: Kymera’s Dupixent-in-a-pill impresses in closely-watched early eczema readout
December 8, 2025
Barron’s: Kymera Therapeutics Stock Heads for Record. Why Investors Are Excited About Its Anti-Inflammatory Drug.
September 19, 2025
Dermatology Times: KT-621 Shows Strong Phase 1 Results as First-in-Class Oral STAT6 Degrader
June 25, 2025
Boston Business Journal: Kymera signs $750M Gilead deal, announces $250M stock offering
June 25, 2025
FirstWord Pharma: Kymera snags Gilead as new partner, while Sanofi opts for next-gen IRAK4 degrader
June 5, 2025
Barron’s: Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial
Featured Presentations & Publications
September 17, 2025
KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects
European Academy of Dermatology & Venereology (EADV) 2025 – Late Breaking Presentation
October 27, 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
American College of Rheumatology (ACR) 2025